Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

A. L. de Groen; Ronald van Eijk; Stefan Bohringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M. Jansen; Inge Briaire-de Bruijn; Fleur A. de Groot; Karin Kleiverda; Liane te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F. M. Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C. E. den Hartog; Lara H. Bohmer; Pancras C. W. Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J. Lugtenburg; Marie Jose Kersten; Steven T. Pals; Hendrik Veelken; Judith V. M. G. Bovee; Arjen H. G. Cleven; Joost S. P. Vermaat

doi:https://doi.org/10.1182/bloodadvances.2021005215

Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

A. L. de Groen, Ronald van Eijk, Stefan Bohringer, Tom van Wezel, Richard Raghoo, Dina Ruano, Patty M. Jansen, Inge Briaire-de Bruijn, Fleur A. de Groot, Karin Kleiverda, Liane te Boome, Valeska Terpstra, Henriette Levenga, Alina Nicolae, Eduardus F. M. Posthuma, Isabelle Focke-Snieders, Lizan Hardi, Wietske C. E. den Hartog, Lara H. Bohmer, Pancras C. W. HogendoornAnke van den Berg, Arjan Diepstra, Marcel Nijland, Pieternella J. Lugtenburg, Marie Jose Kersten, Steven T. Pals, Hendrik Veelken, Judith V. M. G. Bovee, Arjen H. G. Cleven, Joost S. P. Vermaat

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Original language	English
Pages (from-to)	3760-3775
Number of pages	16
Journal	Blood advances
Volume	5
Issue number	19
DOIs	https://doi.org/10.1182/bloodadvances.2021005215
Publication status	Published - 12 Oct 2021

Access to Document

https://doi.org/10.1182/bloodadvances.2021005215

Cite this

de Groen, A. L., van Eijk, R., Bohringer, S., Wezel, T. V., Raghoo, R., Ruano, D., Jansen, P. M., Briaire-de Bruijn, I., de Groot, F. A., Kleiverda, K., te Boome, L., Terpstra, V., Levenga, H., Nicolae, A., Posthuma, E. F. M., Focke-Snieders, I., Hardi, L., den Hartog, W. C. E., Bohmer, L. H., ... Vermaat, J. S. P. (2021). Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype. Blood advances, 5(19), 3760-3775. https://doi.org/10.1182/bloodadvances.2021005215

@article{4326997f38bc4aafb5967da61e0fd6f8,

title = "Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype",

author = "{de Groen}, {A. L.} and {van Eijk}, Ronald and Stefan Bohringer and Wezel, {Tom van} and Richard Raghoo and Dina Ruano and Jansen, {Patty M.} and {Briaire-de Bruijn}, Inge and {de Groot}, {Fleur A.} and Karin Kleiverda and {te Boome}, Liane and Valeska Terpstra and Henriette Levenga and Alina Nicolae and Posthuma, {Eduardus F. M.} and Isabelle Focke-Snieders and Lizan Hardi and {den Hartog}, {Wietske C. E.} and Bohmer, {Lara H.} and Hogendoorn, {Pancras C. W.} and {den Berg}, {Anke van} and Arjan Diepstra and Marcel Nijland and Lugtenburg, {Pieternella J.} and Kersten, {Marie Jose} and Pals, {Steven T.} and Hendrik Veelken and Bovee, {Judith V. M. G.} and Cleven, {Arjen H. G.} and Vermaat, {Joost S. P.}",

note = "Funding Information: This study is funded by the Stichting Fonds Oncologie Holland. Funding Information: Conflict-of-interest disclosure: M.J.K. has received honoraria/ research funding from Kite Pharma, Millennium/Takeda, Mundi-pharma, Gilead Sciences, Bristol Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene, Incyte, and Regeneron. The remaining authors declare no competing financial interests.",

year = "2021",

month = oct,

day = "12",

doi = "https://doi.org/10.1182/bloodadvances.2021005215",

language = "English",

volume = "5",

pages = "3760--3775",

journal = "Blood advances",

issn = "2473-9529",

publisher = "American Society of Hematology",

number = "19",

}

de Groen, AL, van Eijk, R, Bohringer, S, Wezel, TV, Raghoo, R, Ruano, D, Jansen, PM, Briaire-de Bruijn, I, de Groot, FA, Kleiverda, K, te Boome, L, Terpstra, V, Levenga, H, Nicolae, A, Posthuma, EFM, Focke-Snieders, I, Hardi, L, den Hartog, WCE, Bohmer, LH, Hogendoorn, PCW, den Berg, AV, Diepstra, A, Nijland, M, Lugtenburg, PJ, Kersten, MJ , Pals, ST, Veelken, H, Bovee, JVMG, Cleven, AHG & Vermaat, JSP 2021, 'Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype', Blood advances, vol. 5, no. 19, pp. 3760-3775. https://doi.org/10.1182/bloodadvances.2021005215

TY - JOUR

T1 - Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

AU - de Groen, A. L.

AU - van Eijk, Ronald

AU - Bohringer, Stefan

AU - Wezel, Tom van

AU - Raghoo, Richard

AU - Ruano, Dina

AU - Jansen, Patty M.

AU - Briaire-de Bruijn, Inge

AU - de Groot, Fleur A.

AU - Kleiverda, Karin

AU - te Boome, Liane

AU - Terpstra, Valeska

AU - Levenga, Henriette

AU - Nicolae, Alina

AU - Posthuma, Eduardus F. M.

AU - Focke-Snieders, Isabelle

AU - Hardi, Lizan

AU - den Hartog, Wietske C. E.

AU - Bohmer, Lara H.

AU - Hogendoorn, Pancras C. W.

AU - den Berg, Anke van

AU - Diepstra, Arjan

AU - Nijland, Marcel

AU - Lugtenburg, Pieternella J.

AU - Kersten, Marie Jose

AU - Pals, Steven T.

AU - Veelken, Hendrik

AU - Bovee, Judith V. M. G.

AU - Cleven, Arjen H. G.

AU - Vermaat, Joost S. P.

N1 - Funding Information: This study is funded by the Stichting Fonds Oncologie Holland. Funding Information: Conflict-of-interest disclosure: M.J.K. has received honoraria/ research funding from Kite Pharma, Millennium/Takeda, Mundi-pharma, Gilead Sciences, Bristol Myers Squibb, Roche, Celgene, Novartis Pharmaceuticals Corporation, and Amgen. P.J.L. has received honoraria/research funding from Takeda, Servier, Genmab, Roche, Genentech, Celgene, Incyte, and Regeneron. The remaining authors declare no competing financial interests.

PY - 2021/10/12

Y1 - 2021/10/12

UR - http://www.scopus.com/inward/record.url?scp=85117236664&partnerID=8YFLogxK

U2 - https://doi.org/10.1182/bloodadvances.2021005215

DO - https://doi.org/10.1182/bloodadvances.2021005215

M3 - Article

C2 - 34478526

SN - 2473-9529

VL - 5

SP - 3760

EP - 3775

JO - Blood advances

JF - Blood advances

IS - 19

ER -

Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype

Access to Document

Other files and links

Cite this